Skip to search formSkip to main contentSkip to account menu

anecortave acetate

Known as: 4,9(11)-pregnadien-17alpha,21-diol-3,20-dione-21-acetate 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Identification of PDE6D as a molecular target of anecortave acetate via a methotrexate-anchored yeast three-hybrid screen.
Glaucoma and age-related macular degeneration are ocular diseases targeted clinically by anecortave acetate (AA). AA and its… 
Review
2012
Review
2012
New Pharmacologic Approaches to Therapy for Age-Related Macular Degeneration
As a result of a better understanding of molecular mechanisms, a variety of new Pharmacologic treatments have recently been… 
2010
2010
Suppression of corticosteroid-induced ocular hypertension in sheep by anecortave.
OBJECTIVE To confirm the ocular hypotensive effects of anecortave acetate on an ovine model for steroid-induced ocular… 
2009
2009
Natural history of predominantly classic, minimally classic, and occult subgroups in exudative age-related macular degeneration.
2007
2007
Mechanism of retinoblastoma tumor cell death after focal chemotherapy, radiation, and vascular targeting therapy in a mouse model.
PURPOSE To evaluate the mechanism and timing of retinal tumor cell death in the LH(BETA)T(AG) mouse model of retinoblastoma after… 
Review
2007
Review
2007
Preclinical efficacy of anecortave acetate.
2006
2006
ANECORTAVE ACETATE TREATMENT FOR RETINAL ANGIOMATOUS PROLIFERATION: A Pilot Study
Purpose: The purpose of this study was to evaluate anecortave acetate treatment of retinal angiomatous proliferation (RAP), a… 
Review
2006
Review
2006
Anecortave acetate in the treatment of age-related macular degeneration
RETAANE® 15mg (anecortave acetate suspension) is under investigation to treat exudative age-related macular degeneration (AMD… 
Review
2006
Review
2006
A Preliminary Benefit-Risk Assessment of Verteporfin in Age-Related Macular Degeneration
The prevalence of neovascular age-related macular degeneration (AMD) is expected to increase significantly during the next 20… 
2005
2005
Drug pricing for a novel treatment for wet macular degeneration: using incremental cost-effectiveness ratios to ensure societal value.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)